Subsequently, taxol and 10-deacetylbaccatin III (10-DAB III) were extracted from culture filtrates and mycelia of the PCR positive isolates and analyzed by high-performance liquid chromatography and mass spectrometry. The analysis showed that one isolate (SBU-16) produced taxol (6.9 ± 0.2 μg L−1) and its intermediate compound, 10-DAB III (2.2 ± 0.1 μg L−1). The isolate SBU-16 was identified as Stemphylium sedicola SBU-16, according to its morphological check details characteristics as well as the internal transcribed spacer nuclear rDNA gene sequence analysis. Interestingly, this is the first report of the genus Stemphylium as a taxol-producing taxon. Among secondary metabolites with anticancer

activity, taxol (paclitaxel), a complex diterpene obtained from Sorafenib purchase slowly growing Taxus species, is arguably the most important and widely used for clinical applications (Malik et al., 2011). It was originally isolated and characterized from the bark of Taxus brevifolia (Wani et al., 1971). Since the discovery of taxol, considerable energy has been invested in discovering

the means to increase its extraction. A serious obstacle to overcome is the low concentration (0.001–0.05%) of taxol found in the most productive species, T. brevifolia. As it is necessary to take 10 000 kg of Taxus bark or 3000 yew trees to produce only one kilogram of the drug (Schippmann, 2001), a patient with cancer needs approximately 2.5–3 g of paclitaxel (Bedi et al., 1996), which is equivalent to about eight 60-year-old yew trees. Additionally, extraction of taxol from yew trees requires a complex system and specific purification techniques using advanced and expensive technology. Taking into account the facts mentioned above together with the seasonal variation in taxane concentration in Taxus (Cameron & Smith, 2008) and

the ever increasing demand for the drug, there is an urgent need to find other alternative sources of production. Several methods have been developed for taxol production, for example, total chemical synthesis (Holton et al., 1994a, b; Nicolaou et al., 1994), semi-synthesis from its precursor (Holton et al., 1995), and plant tissue cell culture (Zhong, 2002). The complexity of the biosynthetic pathway and its low yield Oxymatrine limit its production by chemical synthesis. Semi-synthesis production is also quite expensive with unstable production and difficulty in purification (Suffness & Wall, 1995). Plant tissue cell culture is an environmentally sustainable source of taxol and offers several advantages as it is not subjected to weather, season, or contamination (Expósito et al., 2009). However, these empirical methods have not been able to meet the increasing world demand for taxanes: 400 kg of taxol is currently needed in the USA and Europe every year (Cameron & Smith, 2008).